Preparations for a December trial between Merck Sharp & Dohme Corporation and Wyeth over four patents for the pneumococcal disease vaccine are underway, and a panel of experts will feature prominently in the high-stakes hearing over the world’s best-selling vaccine.
Generic drug company Alphapharm has lost a bid for documents it claimed would show Sanofi-Aventis suspected as early as 2015 that patents for one of its injector pens may be invalid.
A Federal Court judge has put an appeal by Aristocrat of an IP Australia ruling that revoked four of its gaming patents on hold pending the outcomes of two highly anticipated cases over the patentability of computer software.
ObjectiVision has presented a “limited” and “debatable” case that its source code for a glaucoma testing device was copied, the Federal Court heard Thursday as the trial in a four-year spat with the University of Sydney over IP rights came to a close.
Ophthalmic diagnostic device manufacturer ObjectiVision has made its final pitch to the Federal Court at the end of trial in a long-running intellectual property and contract dispute with the University of Sydney, saying in closing submissions that the school had run a “curious” case.
Generic drug maker Alphapharm is fighting a bid by global pharmaceutical giant Sanofi-Aventis to block the listing of one of its injector pens, saying the proposed injunction should be denied because Sanofi is seeking to amend the patent at issue.
A maker of guard rails used on highways has won a judgment invalidating a rival’s patent, with a judge finding the patent lacks novelty.
A Copyright Tribunal decision that led to substantially lower sound recording licence fees for Foxtel was “beyond the pale” because it compared fees charged to the cable TV giant with those charged to fitness centres, the Full Federal Court heard Wednesday.
Ophthalmic diagnostic device manufacture ObjectiVision can’t file amended claims for damages following a trial in a copyright and contract case against the University of Sydney, with a judge saying the school would be “severely prejudiced” if the new claims were allowed.
Ophthalmic diagnostic device maker ObjectiVision’s amended claims for damages, filed after a 25-day patent hearing, are “outlandish” and “unfair,” the University of Sydney has told the Federal Court.